skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

お客様ごとの個別ニーズに対応するコンサルティング

Pharma_intelligence_consulting

Pharma consulting(ファーマコンサルティング)では、経験豊富なコンサルタントが弊社のデータベース群をフル活用し、かつ、外部の情報ソースも利用してお客様のニーズに合わせた個別の市場調査・分析を行います。

コンサルティングで下記のニーズにお応えします:

  • 自社パイプラインの確率調整済みNPVはどれくらいか?
  • 市場参入時の競合状況はどうなるか?
  • 競争が激しい分野の情報をタイムリーに追跡&視覚化するためにどうすればよい?
  • 承認を受けるための最良の臨床開発経路はどのようなものか?
  • より高い償還価格を実現するには、どのような治験のエンドポイントが役立つか?
  • ある製品にとって最良の臨床試験実施機関をどのように選ぶべきか?
  • 臨床試験のための被験者募集に関する実現可能性とタイムラインはどの程度か?
  • 開発中製品の上市までの時間、成功確率、商業的価値のバランスをどうとるか?

 

Pharma consultingご利用のメリットを1分間の動画にまとめました。ぜひご覧下さい。

 

インフォーマセミナー講演動画
Pharma consultingのシニアディレクター・Timothy Pangが、Pharma consultingサービスのケーススタディを交えて講演を行いました。
1. Bringing data alive: Consulting Case Studies(2018年2月/東京)
2. New horizons, fresh opportunities: Tech, Big Data, and the next pharma wave(2017年11月/東京)

このサービスの特徴

無料の最新記事&レポート

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Pharma consulting: 医療用医薬品の...

    COVID-19 24 hour webinar recordings

    Catch up on any missed COVID-19 24 hour webinar sessions

    Topic Cardiovascular Coronavirus

  • Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Biomedtracker: 開発中医...

    COVID-19 and the impact on the clinical trial space

    COVID-19 and the impact on the clinical trial space

    The effect of COVID-19 on clinical trials, the industry response, and the return to full operations

    Topic Coronavirus clinical-trials

  • Pharmaprojects: 医薬品開発パイプラインのデータベース, Biomedtracker: 開発中医薬品をFD...

    The Race to Find a COVID-19 Treatment - Infographic

    The Race to Find a COVID-19 Treatment - Infographic

    Access this infographic which focuses on Gilead’s drug Remdesivir which currently shows the greatest promise for the likelihood of approval as a possible treatment to effectively treat the virus. The infographic highlights the drug summary and profile, the number of patients in each trial phase, and the history of events that have moved this product through the development process.

    Topic Coronavirus FDA Drug Review

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    A Decade of Biopharma Mergers and Acquisitions and Outlook for 2020 Whitepaper

    A Decade of Biopharma Mergers and Acquisitions and Outlook for 2020 Whitepaper

    Using M&A activity as a barometer for the overall health of the biopharma industry, we explore biopharma’s biggest deals of the past decade and examine what they may presage for the year to come. Dive into key insights on trends, M&A drivers, companies to watch, and more. 

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    A Historic Decade of Deal Making

    A Historic Decade of Deal Making

    In preparation for the webinar, download your free infographic, a snapshot view of M&A’s biggest deals and major players and what their activities indicate for the year ahead.

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Trialtrove: 医療用医薬品の臨床試験情報デ...

    COVID-19 Infographic

    COVID-19 Infographic

    Access the infographic below which explores the number of treatment drugs for COVID-19 currently in clinical trials or in development, events including progress updates, partnerships, regulatory and trial announcements etc, and the number of articles published on COVID-19 as of March 3, 2020. This data has been tracked and reported via Informa Pharma Intelligence’s clinical, regulatory and commercial data and analytics, and news and insight tools including Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet, Medtech Insight, and Generics Bulletin etc.

    Topic Coronavirus

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    Biomedtracker Potential Pivots in 2020

    Biomedtracker Potential Pivots in 2020

    In this infographic, we provide insight into key trials that are expecting developments in the approval process.

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor Healthcare: 医療...

    2020 Early Outlook Webinar

    Anticipate the biggest, most impactful expected catalysts of early 2020 with the guidance and insights from Pharma Intelligence. Building off Biomedtracker’s Early 2020 Outlook report, our live webinar will include market context for these upcoming milestones and additional insights from Datamonitor Healthcare’s Therapeutic Area Directors.

    Topic fda

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Meddevicetracker: 医療機器の市場調...

    38th Annual J.P. Morgan Healthcare Conference Review

    38th Annual J.P. Morgan Healthcare Conference Review

    The 38th Annual J.P. Morgan Healthcare Conference has concluded, and Biomedtracker and Meddevicetracker were there to bring you the important outcomes from the largest and most informative annual healthcare investment symposium in the industry.

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor Healthcare: 医療...

    2019 Post-ASH Conference Report Extract

    Access vital post-ASH meeting reporting from the expert analysts at Datamonitor Healthcare and Biomedtracker.

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor Healthcare: 医療...

    2019 Post-ESMO Conference Report Extract

    2019 Post-ESMO Conference Report Extract

    Tap into insights and highlights from ESMO’s annual meeting of oncology clinicians, researchers, patient advocates, journalists, and members of the pharmaceutical industry.

    Topic Cancer Drug development landscape Research

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    Major Mergers & Acquisitions Highlights from Q1 2019

    Major Mergers & Acquisitions Highlights from Q1 2019

    Biomedtracker boils down all the important mergers and acquisitions activities in Q1.

    Topic Business strategies Company analysis

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Meddevicetracker: 医療機器の市場調...

    Q4 2019 Outlook Report Extract

    Q4 2019 Outlook Report Extract

    What major drug catalysts and events can you expect to see this quarter? Get a view of what's to come with an extract from the full report.

    Topic clinical-trials drug-development-landscape

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    Q3 2019 Catalyst Roundup

    Q3 2019 Catalyst Roundup

    What were the outcomes of critical catalysts featured in Biomedtracker’s Q3 2019 Outlook Report? Find out in the Catalyst Roundup: A Review of Select Catalysts from Last Quarter’s Outlook Report. This data-rich graphic is available now – for free.

    Topic Drug approval Drug review FDA

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor Healthcare: 医療...

    Key potential drug launches 2020

    Key potential drug launches 2020

    Take a longer-term look at key late-stage drugs projected to hit the market in 2020, including new drug classes, major changes to standards of care, and/or large market opportunities across the wide range of indications covered by Biomedtracker and Datamonitor Healthcare.

    Topic drug-approval drug-review drug-development-landscape

医薬品産業専門のジャーナリスト&アナリスト

Consultant

Timothy Pang

Consultant, Senior Director- Pharma consulting

UK

Timothy Pang

Timothy specializes in

  • Business Development & Licensing
  • Commercial Strategy

+24 year(s) experience

お問い合わせ

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com


または下記のフォームよりご連絡下さい。

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。